

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 282 620 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
31.03.2004 Bulletin 2004/14

(51) Int Cl.⁷: **C07D 453/06, A61K 31/439,
A61P 43/00**

(21) Application number: **01936319.1**

(86) International application number:
PCT/EP2001/005008

(22) Date of filing: **03.05.2001**

(87) International publication number:
WO 2001/085727 (15.11.2001 Gazette 2001/46)

(54) **AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE
RECEPTOR AGONISTS**

**AZABIZYKLISCHE CARBAMATE UND IHRE ANWENDUNG ALS ANTAGONISTEN DES ALPHA-7
NIKOTINISCHEN ACETYLCHOLIN REZEPTORS**

**CARBAMATES AZABICYCLIQUES ET LEUR UTILISATION COMME AGONISTES DES
RECEPTEURS NICOTINIQUES ALPHA-7 DE L'ACETYLCHOLINE**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
RO SI

(72) Inventor: **NOZULAK, Joachim**
79423 Heltersheim (DE)

(30) Priority: **05.05.2000 GB 0010955**

(74) Representative: **Gros, Florent et al**
Novartis AG
4002 Basel (CH)

(43) Date of publication of application:
12.02.2003 Bulletin 2003/07

(56) References cited:
WO-A-96/08468 US-A- 5 988 429

(73) Proprietors:
• **Novartis AG**
4002 Basel (CH)
Designated Contracting States:
**BE CH LI CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE TR**
• **Novartis Pharma GmbH**
1230 Wien (AT)
Designated Contracting States:
AT


Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 282 620 B1

Description


[0001] The present invention relates to novel azabicyclic carbamates, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.

[0002] More particularly the invention provides a compound of formula I



I

wherein n is 1 or 2, R₁, R₂ and R₃, independently, are hydrogen or (C₁₋₄)alkyl and A is a group of formula




wherein m is 1, 2 or 3, X is O, S, NH or CH₂ and R₄ and R₅, independently, are hydrogen, halogen, hydroxy, (C₁₋₄)alkyl, (C₁₋₄)alkoxy, (C₁₋₄)alkylthio, (C₁₋₄)alkylamino, nitro, trifluoromethyl or phenyl, in free base or acid addition salt form.

[0003] Halogen denotes fluorine, bromine, chlorine or iodine.

[0004] Any alkyl, alkoxy and alkylthio groups are branched or straight chain groups. They are preferably methyl, methoxy or methylthio groups.


[0005] On account of the asymmetrical carbon atom(s) present in the compounds of formula I and their salts, the compounds may exist in optically active form or in form of mixtures of optical isomers, e.g. in form of racemic mixtures. All optical isomers and their mixtures including the racemic mixtures are part of the present invention.

[0006] In a further aspect, the invention provides a process for the production of the compounds of formula I and their salts, comprising the step of reacting a compound of formula II



II

wherein n, R₁ and R₂ are as defined above, with a compound of formula III




III

wherein R_3 and A are as defined above, and N, N'-carbonyldiimidazole or di(N-succinimidyl)carbonate, and recovering the resulting compound of formula I in free base or acid addition salt form.

[0007] According to a preferred embodiment, in a first step the compound of formula III is reacted with N, N'-carbonyldiimidazole, and the resulting compound is reacted with the compound of formula II.

5 [0008] Alternatively, the compound of formula II can be reacted with a compound of formula IV



wherein R_3 and A are as defined above.

15 [0009] The reactions can be effected according to conventional methods, e.g. as described in the examples.

[0010] Working up the reaction mixtures according to the above processes and purification of the compounds thus obtained may be carried out in accordance to known procedures.

[0011] Acid addition salts may be produced from the free bases in known manner, and vice versa.

20 [0012] Compounds of formula I in optically pure form can be obtained from the corresponding racemates according to well-known procedures. Alternatively, optically pure starting materials can be used.

[0013] The starting materials of formula II, III and IV are known or may be obtained from known compounds, using conventional procedures.

25 [0014] Compounds of formula I and their pharmaceutically acceptable acid addition salts, hereinafter referred to as agents of the invention, exhibit valuable pharmacological properties when tested in vitro and in animals, and are therefore useful as pharmaceuticals.

[0015] In particular, the agents of the invention are $\alpha 7$ nicotinic acetylcholine receptor (nAChR) agonists.

[0016] In functional assays, the agents of the invention display high affinity at the $\alpha 7$ nAChR as shown in the following tests:

30 a) A functional assay for affinity at human $\alpha 7$ nAChR is carried out with a rat pituitary cell line stably expressing the human $\alpha 7$ nAChR. As a read out, the calcium influx upon stimulation of the receptor is used. In this assay, agents of the invention exhibit pEC_{50} values of about 5 to about 8.

35 b) To assess the activity of the agents of the invention on the human neuronal nAChR $\alpha 4\beta 2$, a similar functional assay is carried out using a human epithelial cell line stable expressing the human $\alpha 4\beta 2$ subtype. In this assay, agents of the invention show selectivity for the $\alpha 7$ nAChR subtypes.

40 c) To assess the activity of the compounds of the invention on the "ganglionic subtype" and the muscle type of nicotinic receptor, similar functional assays as described under a) are carried out with a human epithelial cell line stably expressing the human ganglionic subtype or a cell line endogenously expressing the human muscle type of nicotinic receptors. In these assays, agents of the invention display no or little activity on the ganglionic and muscle type of nicotinic receptor subtypes.

45 [0017] In the model of mice showing sensory gating deficit (DBA/2-mice) described by S. Leonard et al. in Schizophrenia Bulletin 22, 431-445 (1996), the agents of the invention induce significant sensory gating at concentrations of about 10 to about 40 μM .

50 [0018] The agents of the invention are therefore useful for the treatment of psychotic disorders such as schizophrenia, mania, depression and anxiety, and for the treatment of neurodegenerative disorders such as senile dementia, Alzheimer's disease and other intellectual impairment disorders, such as attention deficit hyperactivity disorders (ADHD); Parkinson's disease, Huntington's chorea, amyotrophic lateral sclerosis and multiple sclerosis. The usefulness of $\alpha 7$ nAChR agonists in neurodegeneration is documented in the literature, e.g. in Wang et al., J. biol. Chem. 275, 5626-5632 (2000).

55 [0019] For the above-mentioned indications, the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.01 to about 100, preferably from about 0.1 to about 50 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 1 to about 500, preferably from about 5 to about 300 mg of an agent of the invention conveniently administered, for example, in divided doses up to four times a day or in

sustained release form.

[0020] The agent of the invention may be administered by any conventional route, in particular enterally, preferably orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injectable solutions or suspensions.

5 [0021] The preferred compound is the stereoisomer of the (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester, the succinate of which has a melting point of 83-84°C and which has an optical rotation of +14.6° (c=1; water, 20°C, 589 nm), which is the compound of Example 61.

[0022] In accordance with the foregoing, the present invention also provides an agent of the invention, for use as a pharmaceutical, e.g. for the treatment of any condition mentioned above.

10 [0023] The present invention furthermore provides a pharmaceutical composition comprising an agent of the invention in association with at least one pharmaceutical carrier or diluent. Such compositions may be manufactured in conventional manner. Unit dosage forms contain, for example, from about 0.25 to about 150, preferably from about 1 to about 25 mg of a compound according to the invention.

[0024] Moreover the present invention provides the use of an agent of the invention, for the manufacture of a medicament for the treatment of any condition mentioned above.

15 [0025] The following examples illustrate the invention.

Example 1 : (1-Aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-phenyl-ethyl ester

20 ***Imidazole-1-carboxylic acid 1-phenyl-ethyl ester***

[0026] To a solution of DL-1-phenylethanol 1.21 ml (10.0 mmol) in 10ml tetrahydrofuran, N,N'-carbonyldiimidazole 1.70 g (10.5 mmol) is added. The white suspension is heated up to 50°C and stirred for 40 minutes at this temperature. The reaction mixture is cooled and evaporated. The crude product is purified by flash chromatography (hexane / ethyl acetate 80 / 20) to yield the title product as colorless oil.

(1-Aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-phenyl-ethyl ester

30 [0027] To a solution of imidazole-1-carboxylic acid 1-phenyl-ethyl ester 0.50 g (2.31 mmol) in 5 ml dimethylformamide, 3-aminoquinuclidine dihydrochloride 0.46 g (2.31 mmol) and sodium carbonate 0.49 g (4.62 mmol) are added. The suspension is heated up to 80 °C and stirred for 18 hours at this temperature. The reaction mixture is then cooled and extracted with water and ethylacetate. The combined organic phases are dried and evaporated. The oily residue is dried, dissolved in ether and acidified with a 4 M hydrochloric acid dioxane solution. The precipitating crystals are filtered, washed with ether and dried to give the title product. Mp = 71 - 72 °C (decomposition).

35 **Example 2: (1-Aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid benzyl ester**

[0028] 3-Aminoquinuclidine dihydrochloride 996 mg (5.0 mmol) is added slowly to a stirred suspension of 676 mg (15.5 mmol) sodium hydride (dispersion 55%) in dimethylformamide (15 ml). Thereafter the suspension is stirred for another 90 minutes at room temperature and then carbobenzoxy chloride 0.72 ml (5.1 mmol) is added slowly. After another two hours at room temperature, the suspension is quenched by carefully adding water. The solvent is then evaporated at 70 °C / 16 mbar. The residue is taken up in water and ethyl acetate. The organic phase is separated and the water phase two-times re-extracted with ethyl acetate. The combined organic phase is dried and evaporated to give the crude oily product which is taken up in dioxane and 0.72 ml of a 4M hydrochloric acid is added. The precipitating product is recrystallised from dioxane/ether to give the hydrochloride of the title product. Mp=192 - 193 °C.

Example 3 : (R)-(+)-(1-Aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid benzyl ester

50 [0029] Sodium hydride (dispersion 55%) 0.33 g (7.5 mmol) is washed with petrolether and the solvent is removed by separation (decantation). Then, the sodium hydride is carefully suspended in dimethylformamide (12.5 ml). To this suspension (R)-(+)-3-aminoquinuclidine dihydrochloride 0.50 g (2.5 mmol) is added. The initially exothermic reaction is then stirred at room temperature for one hour and then carbobenzoxy chloride 0.39 ml (2.75 mmol) is added to the reaction mixture within 15 minutes. The again initially exothermic reaction is stirred at room temperature for 90 minutes, then the mixture is poured into 10% brine (NaCl/water solution) and then four-times extracted with toluene. The combined organic phases are dried and evaporated. The crude oily residue is dissolved in dioxane (5 ml) and 0.31 ml of a 4 M hydrochloric acid is added. The mixture is then stirred at room temperature till the product precipitates. The crystals are filtered, washed with dioxane and ether and dried to give the title product. Mp = 228 - 229 °C. Optical rotation +6.3 ° (c=0.5, water).

Example 4: (S)-(-)-(1-Aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid benzyl ester

[0030] Sodium hydride (dispersion 55%) 0.33 g (7.5 mmol) is washed with petrolether and the solvent is removed by separation (decantation). Then, the sodium hydride is carefully suspended in dimethylformamide (12.5 ml). To this suspension (S)-(-)-3-aminoquinuclidine dihydrochloride 0.50 g (2.5 mmol) is added. The initially exothermic reaction is then stirred at room temperature for one hour and then carbobenzoxy chloride 0.39 ml (2.75 mmol) is added to the reaction mixture within 15 minutes. The again initially exothermic reaction is stirred at room temperature for 90 minutes then the mixture is poured into 10% brine (NaCl/water solution) and then four-times extracted with toluene. The combined organic phases are dried and evaporated. The crude oily residue is dissolved in dioxane (5 ml) and 0.31 ml of a 4 M hydrochloric acid is added. The mixture is then stirred at room temperature till the product precipitates. The crystals are filtered, washed with dioxane and ether and dried to give the title product. Mp = 221 - 223 °C. Optical rotation -8.0 ° (c=0.5, water).

Example 5: (1-Aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 4-butyl-benzyl ester

[0031] Triethylamine 1.05 ml (7.5 mmol) and 0.80 g di-(N-succinimidyl)carbonate are added to a solution of (4-butyl-phenyl)methanol 0.47 ml (2.75 mmol) in 15 ml dichloromethane. The initial suspension is stirred at room temperature for 45 minutes to become a clear solution. This mixture is added dropwise to a solution of 3-aminoquinuclidine 0.32 g (2.5 mmol) and 0.52 ml (1.5 mmol) triethylamine in 10 ml dichloromethane. The reaction mixture is subsequently stirred for another two hours at room temperature. Afterwards the mixture is washed with 20 ml water. The organic phase is separated, dried and evaporated. The crude product is dissolved in 5 ml dichloromethane and acidified with a saturated solution of hydrochloric acid in ether. By addition of 50 ml ether a white product precipitates. The crystals are filtered, washed with ether and dried to give the title product. Mp = 174 - 175°C (decomposition).

[0032] The following compounds of formula I wherein n is 2, R₁ and R₂ are hydrogen and A is a substituted phenyl group can be prepared in analogy to Examples 1, 2 or 5.

Example	R ₃	R ₄	R ₅	Mp / Optical Rotation
6	H	o-OMe	H	89-90°C (hydrochloride)
7	H	2-OMe	3-OMe	93-95°C (hydrochloride)
8	H	p-phenyl	H	193-195°C (hydrochloride)
9	H	o-Br	H	203-204°C (hydrochloride)
10	H	o-NO ₂	H	177-178°C (hydrochloride)
11	H	p-NO ₂	H	89-90°C (hydrochloride)
12	H	2-OMe	5-Br	147-149°C (hydrochloride)
13	H	m-phenoxy	H	82-83°C (hydrochloride)
14	H	o-Cl	H	82-83°C (hydrochloride)
15	H	3-NO ₂	5-NO ₂	93-94°C (hydrochloride)
16	H	3-Cl	4-Cl	*
17	H	m-OMe	H	139-140°C (hydrochloride)
18	H	3-NO ₂	4-Me	86-88°C (hydrochloride)
19	H	3-Me	5-Me	183-184°C (hydrochloride)
20	H	p-CF ₃	H	143-144°C (hydrochloride)
21	H	o-Me	H	174-176°C (hydrochloride)
22	H	p-Me	H	194-196°C (hydrochloride)
23	H	p-isopropyl	H	235°C (hydrochloride)
24	Me	p-Me	H	168-170°C (hydrochloride)

Me = Methyl

* IR: Carbonyl absorption at 1695 cm⁻¹

EP 1 282 620 B1

(continued)

Example	R ₃	R ₄	R ₅	Mp / Optical Rotation
25 cis/trans racemic mixture	Me	H	H	71-72 °C (hydrochloride)
26 Stereoiso mer-1	Me	H	H	182-184 °C (hydrochloride) ; optical rotation: + 32.4 ° (c=1; water, 24 °C, 589 nm)
27 Stereoiso mer-2	Me	H	H	151-152 °C (succinate) optical rotation: - 9.7 ° (c=1; methanol, 22 °C, 589 nm)
28 Stereoiso mer-3	Me	H	H	optical rotation: + 12.5 ° (c=1; methanol, 20 °C, 589 nm)
29 Stereoiso mer-4	Me	H	H	117-119 °C (fumarate) optical rotation: - 25.0 ° (c=1; methanol, 20 °C, 589 nm)
30	H	3-OMe	5-OMe	179-180 °C (hydrochloride)
31	H	3-Me	4-NO ₂	165-167 °C (hydrochloride)
32	Me	2-Cl	4-Cl	212-214 °C (hydrochloride)
33	H	p-Ethyl	H	208-209 °C (hydrochloride)
34	H	p-Br	H	190-191 °C (hydrochloride)
35	H	3-CF ₃	5-CF ₃	157-158 °C (hydrochloride)
36	H	p-SMe	H	164-166 °C (hydrochloride)
37	H	2-NO ₂	5-Me	198-199 °C (hydrochloride)
38	H	3-OMe	4-OMe	221-223 °C (hydrochloride)
39	H	2-Cl	6-Cl	251-252 °C (hydrochloride)
40	H	p-CO ₂ Me	H	220-222 °C (hydrochloride)
41	Me	p-tButyl	H	232-233 °C (hydrochloride)
42	Ethyl	H	H	**
43	Me	p-Cl	H	132-135 °C (hydrochloride)
44	Me	o-Me	H	219-220 °C (hydrochloride)
45	Me	p-Br	H	163-165 °C (hydrochloride)
46	Me	3-Cl	4-Cl	240-241 °C (hydrochloride)
47	Me	p-F	H	219-220 °C (hydrochloride)
48	H	m-Br	H	186-187 °C (hydrochloride)
49	H	m-Me	H	174-175 °C (hydrochloride)
50	H	m-OBenzyl	H	168-169 °C (hydrochloride)
51	H	2-Cl	5-Cl	205-207 °C (hydrochloride)
52	H	2-OMe	5-OMe	162-163 °C (hydrochloride)
53	H	2-NO ₂	4-Cl	204-205 °C (hydrochloride)
54 cis/trans racemic mixture	Me	o-Cl	H	230-232 °C (hydrochloride)
55 Stereoiso mer-1	Me	o-Cl	H	229-230 °C (hydrochloride) optical rotation: - 8.6 ° (c=1; water, 20 °C, 589 nm)
56 Stereoiso mer-2	Me	o-Cl	H	255-257 °C (hydrochloride) optical rotation: + 26.8 ° (c=1; water, 22 °C, 589 nm)

** IS: Carbonyl absorption at 1712 cm⁻¹

EP 1 282 620 B1

(continued)

Example	R ₃	R ₄	R ₅	Mp / Optical Rotation
57 Stereoiso mer-3	Me	o-Cl	H	229-230 °C (hydrochloride) optical rotation: + 8.9 ° (c=1; water, 20 °C, 589 nm)
58 Stereoiso mer-4	Me	o-Cl	H	257-258 °C (hydrochloride) optical rotation: - 30.9 ° (c=1; water, 22 °C, 589 nm)
59 Stereoiso mer-1	Me	o-F	H	83-84 °C (succinate) optical rotation: + 15.4 ° (c=1; water, 20 °C, 589 nm)
60 Stereoiso mer-2	Me	o-F	H	146-147 °C (succinate) optical rotation: + 2.5 ° (c=1; water, 20 °C, 589 nm)
61 Stereoiso mer-3	Me	o-F	H	83-84 °C (succinate) optical rotation: + 14.6 ° (c=1; water, 20 °C, 589 nm)
62 Stereoiso mer-4	Me	o-F	H	136-137 °C (succinate) optical rotation: - 4.8 ° (c=1; water, 20 °C, 589 nm)

Example 63: (1-Aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid benzo[1,3]dioxol-5-ylmethyl ester

[0033] Prepared in analogy to example 1, 2 or 5.
Mp (hydrochloride) = 186-187°C.

Example 64: (1-Aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid benzo[1,3]dioxol-4-nitro-5-ylmethyl ester

[0034] Prepared in analogy to example 1, 2 or 5.
Mp (hydrochloride) = 216-218 °C.

Example 65: (1-Aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 3,4,5-trimethoxy-benzyl ester


[0035] Prepared in analogy to example 1, 2 or 5.
Mp (hydrochloride) = 211-212 °C.

Example 66 1-Aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid benzo[1,2,5]thiadiazol-5-ylmethyl ester

[0036] Prepared in analogy to example 1, 2 or 5.
IS: Carbonyl absorption at 1718 cm⁻¹


Claims

1. A compound of formula I




I

wherein n is 1 or 2, R₁, R₂ and R₃, independently, are hydrogen or (C₁₋₄)alkyl and A is a group of formula




wherein m is 1, 2 or 3, X is O, S, NH or CH_2 and R_4 and R_5 , independently, are hydrogen, halogen, hydroxy, (C_{1-4}) alkyl, (C_{1-4}) alkoxy, (C_{1-4}) alkylthio, (C_{1-4}) alkylamino, nitro, trifluoromethyl or phenyl, in free base or acid addition salt form.

2. A compound according to claim 1 which is a stereoisomer of the (1-azabicyclo[2.2.2]oct-3-yl)carbamic acid 1-(2-fluorophenyl)-ethyl ester, in free base or acid addition salt form.
3. A compound according to claim 1 which is the stereoisomer of the (1-azabicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester, the succinate of which has a melting point of $83-84^\circ\text{C}$ and which has an optical rotation of $+14.6^\circ$ ($c=1$; water, 20°C , 589 nm), in free base or acid addition salt form.
4. A process for the preparation of a compound of formula I as defined in claim 1, or a salt thereof, which comprises the step of reacting a compound of formula II




wherein n , R_1 and R_2 are as defined in claim 1, with a compound of formula III




wherein R_3 and A are as defined in claim 1, and N , N' -carbonyldiimidazole or di(N -succinimidyl)carbonate, and recovering the resulting compound of formula I in free base or acid addition salt form.

5. A process for the preparation of a compound of formula I as defined in claim 1, or a salt thereof, which comprises the step of reacting a compound of formula II



wherein n, R₁ and R₂ are as defined in claim 1, with a compound of formula IV




10 wherein R₃ and A are as defined above, and recovering the resulting compound of formula I in free base or acid addition salt form.


6. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.
- 15 7. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment of psychotic and neurodegenerative disorders.
8. A pharmaceutical composition comprising a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.
- 20 9. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of psychotic and neurodegenerative disorders.

25 **Patentansprüche**

1. Verbindung der Formel I




35 worin n für 1 oder 2 steht, R₁, R₂ und R₃ unabhängig für Wasserstoff oder C₁-C₄ Alkyl stehen und A für eine Gruppe der Formeln steht



worin m für 1, 2 oder 3 steht, X für O, S, NH oder CH₂ steht und R₄ und R₅ unabhängig für Wasserstoff, Halogen, Hydroxy, C₁-C₄ Alkyl, C₁-C₄ Alkoxy, C₁-C₄ Alkylthio, C₁-C₄ Alkylamino, Nitro, Trifluomethyl oder Phenyl stehen, in Form der freien Base oder in Säureadditionssalzform.

2. Verbindung nach Anspruch 2, die ein Stereoisomer des (1-Aza-bicyclo[2.2.2]oct-3-yl)carbaminsäure-1-(2-fluorphenyl)ethylesters in Form der freien Base oder in Säureadditionssalzform ist.
3. Verbindung nach Anspruch 1, die das Stereoisomer des (1-Aza-bicyclo[2.2.2]oct-3-yl)carbaminsäure-1-(2-fluorphenyl)ethylesters ist, dessen Succinat einen Schmelzpunkt von 83-84°C aufweist und das eine optische Drehung von +14,6° (c = 1, Wasser, 20°C, 589 nm) aufweist, in Form der freien Base oder in Säureadditionssalzform.
4. Verfahren zur Herstellung einer Verbindung der Formel I nach Anspruch 1 oder eines Salzes hiervon, das den Schritt der Umsetzung einer Verbindung der Formel II




worin n, R₁ und R₂ wie in Anspruch 1 definiert sind, mit einer Verbindung der Formel m,




worin R₃ und A wie in Anspruch 1 definiert sind, und N,N'-Carbonyldiimidazol oder Di-(N-succinimidyl)carbonat und der Gewinnung der entstehenden Verbindung der Formel I in Form der freien Base oder in Säureadditionssalzform umfasst.

5. Verfahren zur Herstellung einer Verbindung der Formel I nach Anspruch 1 oder eines Salzes hiervon, das den Schritt der Umsetzung einer Verbindung der Formel II



worin n, R₁ und R₂ wie in Anspruch 1 definiert sind, mit einer Verbindung der Formel IV



worin R₃ und A wie oben definiert sind, und der Gewinnung der entstehenden Verbindung der Formel I in Form der freien Base oder in Säureadditionssalzform umfasst.


6. Verbindung nach Anspruch 1 in Form der freien Base oder in pharmazeutisch annehmbarer Säureadditionssalzform zur Verwendung als Pharmazeutikum.
7. Verbindung nach Anspruch 1 in Form der freien Base oder in pharmazeutisch annehmbarer Säureadditionssalzform zur Verwendung bei der Behandlung von psychotischen und neurodegenerativen Störungen.

8. Pharmazeutische Zusammensetzung, die eine Verbindung nach Anspruch 1 in Form der freien Base oder in pharmazeutisch annehmbarer Säureadditionssalzform zusammen mit einem pharmazeutischen Träger oder Verdünnungsmittel umfasst.


9. Verwendung einer Verbindung nach Anspruch 1 in Form der freien Base oder in pharmazeutisch annehmbarer Säureadditionssalzform zur Herstellung eines Arzneimittels zur Behandlung von psychotischen und neurodegenerativen Störungen.

Revendications

1. Composé de formule I :



dans laquelle n vaut 1 ou 2, R₁, R₂ et R₃ représentent indépendamment l'hydrogène ou un groupe alkyle en C₁ à C₄, et A est un groupe de formule :




dans laquelle m vaut 1, 2 ou 3, X représente O, S, NH ou CH₂, et R₄ et R₅ représentent indépendamment l'hydrogène, un halogène, un groupe hydroxy, alkyle en C₁ à C₄, alcoxy en C₁ à C₄, alkylthio en C₁ à C₄, alkyle en C₁ à C₄-amino, nitro, trifluorométhyle ou phényle, sous forme d'un base libre ou d'un sel d'addition d'acide.

2. Composé suivant la revendication 1, qui est un stéréoisomère de l'ester 1-(2-fluorophényl)éthylque de l'acide (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamique, sous forme de base libre ou sous forme d'un sel d'addition d'acide.


3. Composé suivant la revendication 1, qui est le stéréoisomère de l'ester 1-(2-fluorophényl)éthylque de l'acide (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamique, dont le succinate a un point d'ébullition de 83-84°C et une rotation optique de +14,6° (c=1 ; eau, 20 °C, 589 nm), sous forme de base libre ou sous forme d'un sel d'addition d'acide.

4. Procédé de préparation d'un composé de formule I tel que défini dans la revendication 1, ou d'un de ses sels, qui comprend l'étape consistant à amener à réagir un composé de formule II :



II


dans laquelle n, R₁ et R₂ sont tels que définis dans la revendication 1, avec un composé de formule III :



III


dans laquelle R₃ et A sont tels que définis dans la revendication 1, et le N,N'-carbonyldiimidazole ou le carbonate de di-(N-succinimidyle), et à récupérer le composé résultant de formule I sous forme de base libre ou sous forme d'un sel d'addition d'acide.

5. Procédé de préparation d'un composé de formule I tel que défini dans la revendication 1, ou d'un de ses sels, qui comprend l'étape consistant à amener à réagir un composé de formule II :



II

dans laquelle n, R₁ et R₂ sont tels que définis dans la revendication 1, avec un composé de formule IV :



IV

dans laquelle R₃ et A sont tels que définis ci-dessus, et la récupération du composé de formule I sous forme de base libre ou sous forme d'un sel d'addition d'acide.

6. Composé suivant la revendication 1 sous forme de base libre ou sous forme d'un sel d'addition d'acide pharmaceutiquement acceptable, à utiliser comme médicament.
7. Composé suivant la revendication 1 sous forme de base libre ou sous forme d'un sel d'addition d'acide pharmaceutiquement acceptable, à utiliser dans le traitement de troubles psychotiques et neurodégénératifs.
8. Composition pharmaceutique comprenant un composé suivant la revendication 1 sous forme de base libre ou sous forme d'un sel d'addition d'acide pharmaceutiquement acceptable, en association avec un support ou diluant pharmaceutique.
9. Utilisation d'un composé suivant la revendication 1 sous forme de base libre ou sous forme d'un sel d'addition d'acide pharmaceutiquement acceptable, pour la fabrication d'un médicament pour le traitement de troubles psychotiques et neurodégénératifs.